ABSTRACT We report here the draft genome sequences of two clinically isolated Acinetobacter baumannii strains. These samples were obtained from patients at the University of Colorado Hospital in 2007 and 2013 and encode an estimated 20 and 13 resistance genes, respectively. P athogens in the genus Acinetobacter have been named as a serious threat to public health (1), with Acinetobacter baumannii in particular capable of increasing risk of mortality up to 70% (2). A. baumannii is a decidedly adaptive species, demonstrating a wealth of mechanisms for evading diverse antibiotic classes, including on horizontally transferred resistance islands in the genome (2, 3) and resistance-conferring plasmids (4). A. baumannii is also able to survive for extended durations on dry surfaces (5). These factors together have allowed for a high frequency of multidrug-resistant nosocomial A. baumannii infections worldwide, with diminishing options for treatment. Characterization of clinically isolated A. baumannii strains will enable development of more effective treatment strategies.
nine rRNAs, two CRISPRs, and 3,882 coding sequences. The 13 resistance genes found include two aminoglycosides (strA and strB), eight ␤-lactams (ADC-76, blaA1, blaA2, mbl, OXA-24, OXA-65, TEM-116, and a zinc-dependent hydrolase), two chloramphenicols (catA1 and cmlB1), and one sulfonamide (sulII). OXA-24 is the only gene not on the genome; it appears to be on a plasmid, similar to GenBank JN207494.1 (4).
We validated resistances by plating on solid media with antibiotics and found that both strains are able to grow in tetracycline, ampicillin, and chloramphenicol. CU060707 cannot grow in meropenem. CU032113 grows in meropenem, but not in gentamicin or erythromycin. Both isolates are resistant to ciprofloxacin, indicating that gyrA and/or parC are mutated (10, 11) . Accession number(s). This whole-genome shotgun sequencing project has been deposited in GenBank under the accession numbers LXWY00000000 (for CU060707) and LXYW00000000 (for CU032113).
